You are here: Industry Insights > Solid Tumor

News List

Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
InnoCare Pharma announced 2023 interim results as of 30 June 2023 PharmaSources
September 04, 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
InnoCare Releases 2022 Annual Results and Business Highlights PharmaSources
March 29, 2023
28 March 2023,InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2022 annual results as of 31 December 2022.
InnoCare Releases 2021 Annual Results and Business Highlights InnoCare
March 23, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing...
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor prnasia
August 03, 2021
Jacobio Pharmaceuticals today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.
Anti-tumor agent from the intestine worldpharmanews
July 13, 2021
It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson's could have their causes here - not ...
With Diversified CAR-T Products in Hand, CARSGEN Applied for IPO in Hong Kong, S.A.R., China to Challenge the Treatment of Solid Tumor PharmaSources/Chuxin
July 09, 2021
On June 18, CARSGEN Therapeutics, a pioneer in the field of CAR-T cell therapy, officially listed on the Hong Kong, S.A.R., China Stock Exchange, offering 94.747 million shares, priced at HK $32.80 per share, raising a net of about HK $2.94 billion.
Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies prnasia
May 20, 2021
Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the ...
GEMoaB Announces Trial with Solid Tumor Candidate from UniCAR Cellular Immunotherapy Platform americanpharmaceuticalreview
December 24, 2020
GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.
Samsung Biologics signs development agreement with Panolos for solid tumor treatment prnasia
September 17, 2020
Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.

Previous page 1 2 Next page